Topical VEGFr antagonist does not reduce need for intravitreal ranibizumab

• Posted on: Apr 12 2022
• By: Saratoga Opthalmology
• Leave a response

This study examined the efficacy of topical acrizanib in reducing the need for intravitreal anti-VEGF therapy in patients with neovascular age-related macular degeneration (AMD).
Source: AAO

Posted in: Uncategorized